Exscientia plc
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Hallett
- Full Time Employees
- 483
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- The SchrOedinger Building Oxford United Kingdom OX4 4GE
- IPO Date
- Oct 1, 2021
- CIK
- 0001865408
- Website
- exscientia.ai
- Similar Companies
- Business
- Exscientia plc, an artificial intelligence-driven pharmatech company founded in 2013 and headquartered at the Schrödinger Building on Oxford Science Park in Oxford, UK, discovers, designs and develops differentiated small-molecule drugs for oncology, immunology and other high-unmet-need diseases using its proprietary end-to-end precision platform that integrates AI-powered DesignStudio for generative molecular design, AutomationStudio for robotic synthesis and testing, Precision Target for disease-target identification via machine learning on genetic and literature data, Precision Experiment for biophysical validation, and Precision Medicine for patient-specific optimization; the platform supports internal pipelines and collaborations including with Sanofi, Bristol Myers Squibb, Merck KGaA and GT Apeiron. Exscientia operates globally with facilities in the UK (Oxford, Dundee), US (Miami, Cambridge MA), Austria (Vienna), and Japan (Osaka), targeting pharmaceutical partners and advancing candidates like the AI-designed oral CDK7 inhibitor GTAEXS617, for which it acquired full rights from GT Apeiron in July 2024 for $20 million upfront plus royalties. In August 2024, Exscientia entered a definitive agreement to merge with Recursion Pharmaceuticals in an all-stock transaction valued at $688 million, completed in 2024 to form a combined entity with approximately $850 million in cash, enhanced AI capabilities across biology and chemistry, and potential $200 million in near-term milestones from existing partnerships; the business combination positions the integrated company as a global leader in technology-enabled drug discovery with ongoing operations in the US, UK and Europe.
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Recursion and Exscientia Shareholders Approve the Proposed Combination
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of RXRX and EXAI
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024
Brilliant NextGen Will Expand Solutions for Builders Through its Acquisition by Private Investors
Exscientia Business Update for Second Quarter and First Half 2024
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
Biotech firm Recursion to buy smaller peer Exscientia for $688 million
3 Small-Cap Stocks With Explosive 2X Growth Potential
Contact Levi & Korsinsky by June 25, 2024 Deadline to Join Class Action Against Exscientia plc(EXAI)
Exscientia plc Class Action: Levi & Korsinsky Reminds Exscientia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 25, 2024 - EXAI
Exscientia Plc Investors With Losses Are Encouraged By The Schall Law Firm To Start Communication Be Aware Of The Deadline In This Case
Shareholders that lost money on Exscientia plc(EXAI) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
Investors in Exscientia plc Should Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAI
Investors in Exscientia plc Should Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAI